OncBioMune Submits Phase 2 Protocol for Prostate Cancer Vaccine

OncBioMune Pharmaceuticals has submitted to FDA a Phase 2 clinical trial protocol for ProscaVax, a novel therapeutic cancer vaccine for early stage prostate cancer. In the trial, ProscaVax will be evaluated for safety, tolerability and efficacy as a treatment for patients with a new disease diagnosis and who have chosen to forego standard approved therapies in favor of careful monitoring for disease progression (also known as “active surveillance”), according to the company.

OncBioMune describes ProscaVax as an immunotherapeutic cancer vaccine consisting of a combination of the tumor-associated prostate specific antigen (PSA) with biological adjuvants interleukin-2 and granulocyte-macrophage colony-stimulating factor. Clinical data in late-stage patients has shown signs of efficacy with respect to an increased immune response and slowing tumor progression.